Anti-V2 antibody deficiency in individuals infected with HIV-1 in Cameroon.
Virology
; 529: 57-64, 2019 03.
Article
em En
| MEDLINE
| ID: mdl-30665098
ABSTRACT
The results of the RV144 vaccine clinical trial showed a correlation between high level of anti-V1V2 antibodies (Abs) and a decreased risk of acquiring HIV-1 infection. This turned the focus of HIV vaccine design to the induction of elevated levels of anti-V2 Abs to increase vaccine efficacy. In plasma samples from HIV-1 infected Cameroonian individuals, we observed broad variations in levels of anti-V2 Abs, and 6 of the 79 plasma samples tested longitudinally displayed substantial deficiency of V2 Abs. Sequence analysis of the V2 region from plasma viruses and multivariate analyses of V2 characteristics showed a significant difference in several features between V2-deficient and V2-reactive plasma Abs. These results suggest that HIV vaccine immunogens containing a shorter V2 region with fewer glycosylation sites and higher electrostatic charges can be beneficial for induction of a higher level of anti-V2 Abs and thus contribute to HIV vaccine efficacy.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Anticorpos Anti-HIV
/
Infecções por HIV
/
HIV-1
Tipo de estudo:
Clinical_trials
Limite:
Humans
País/Região como assunto:
Africa
Idioma:
En
Revista:
Virology
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Estados Unidos